title: Overview of Histone Deacetylase Inhibitors in Haematological Malignancies.
abstract: Histone deacetylase inhibitors (HDACi) can induce hyperacetylation of both histone and non-histone target resulting in epigenetic reprogramming and altered activity, stability and localisation of non-histone proteins to ultimately mediate diverse biological effects on cancer cells and their microenvironment. Clinical trials have demonstrated single agent HDACi to have activity in hematological malignancies, in particular T-cell lymphoma and Hodgkin lymphoma. Combination strategies with standard therapies based on pre-clinical data are being employed with significant success due to their excellent side effect profile. Correlative studies will provide valuable information on the sub-groups of patients more likely to respond or be resistant to HDACi therapy, while long-term monitoring for toxicities is also needed.
authors.affiliation: Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia. mark.bishton@petermac.org.
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Bishton
authors.affiliation: Cancer Immunology Research, Peter MacCallum Cancer Centre, Melbourne, Australia.|University of Melbourne, Parkville, Melbourne, Australia.
authors.forename: Ricky W
authors.initials: RW
authors.lastname: Johnstone
authors.affiliation: Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Australia.
authors.forename: Michael
authors.initials: M
authors.lastname: Dickinson
authors.affiliation: Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Australia.
authors.forename: Simon
authors.initials: S
authors.lastname: Harrison
authors.affiliation: Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, Australia.|University of Melbourne, Parkville, Melbourne, Australia.
authors.forename: H Miles
authors.initials: HM
authors.lastname: Prince
keywords: Clinical studies; Haematology; Histone deacetylase inhibitors